Investigational Drug Information for nirmatrelvir
✉ Email this page to a colleague
What is the drug development status for nirmatrelvir?
nirmatrelvir is an investigational drug.
There have been 23 clinical trials for nirmatrelvir.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2023.
The most common disease conditions in clinical trials are COVID-19, Severe Acute Respiratory Syndrome, and Post-Acute COVID-19 Syndrome. The leading clinical trial sponsors are Pfizer, University Hospital, Geneva, and National Taiwan University Hospital.
There is one US patent protecting this investigational drug and forty-four international patents.
Summary for nirmatrelvir
| US Patents | 1 |
| International Patents | 44 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2023-01-21) |
| Vendors | 27 |
Recent Clinical Trials for nirmatrelvir
| Title | Sponsor | Phase |
|---|---|---|
| RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | Kanecia Obie Zimmerman | Phase 2 |
| A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin | Pfizer | Phase 1 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities | National Taiwan University Hospital | Phase 2/Phase 3 |
Clinical Trial Summary for nirmatrelvir
Top disease conditions for nirmatrelvir
Top clinical trial sponsors for nirmatrelvir
International Patents for nirmatrelvir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| nirmatrelvir | Argentina | AR123111 | 2040-09-03 | ⤷ Sign Up |
| nirmatrelvir | Australia | AU2021266232 | 2040-09-03 | ⤷ Sign Up |
| nirmatrelvir | Australia | AU2022202158 | 2040-09-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
